Results 181 to 190 of about 29,030 (239)

Human calprotectin as a novel biomarker in multiple sclerosis: Can it differentiate disease stages? [PDF]

Medicine (Baltimore)
Soker EB, Erdem M, Ozdogru D, Tamam Y.
europepmc   +1 more source

MS Fatigue Post High-Efficacy Treatment. [PDF]

Eur J Neurol
Sales C, Patel R, Wijeratne T, Bruestle A, Cherbuin N.   +4 more
europepmc   +1 more source

Differential effect of Fingolimod and Natalizumab treatments on B lymphocyte subpopulations and humoral responses in patients with relapsing remitting multiple sclerosis [PDF]

, 2014
Μπουλογιάννη, Ιουλία
core  

Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study. [PDF]

J Neurol Neurosurg Psychiatry
Mariottini A, Mazzeo AC, Simonetti E, Boncompagni R, Covicchio J, Barilaro A, Cutini I, Di Cristinzi M, Gozzini A, Mattei A, Mealli F, Repice AM, Nozzoli C, Massacesi L.   +13 more
europepmc   +1 more source

A role for DICAM⁺ mononuclear phagocytes in controlling neuroinflammation in multiple sclerosis. [PDF]

Front Immunol
von Essen MR, Hansen MM, El Mahdaoui S, Hvalkof VH, Hansen MB, Buhelt S, Sellebjerg F.   +6 more
europepmc   +1 more source

Evaluation of Selected Serum Adipocytokines in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Immunomodulatory Second-Line Drugs. [PDF]

Int J Mol Sci
Adamczyk B, Morawiec N, Kwinta R, Rakoca M, Wawrzyniak S, Zalejska-Fiolka J, Sowa A, Sawa K, Adamczyk-Sowa M.   +8 more
europepmc   +1 more source

Natalizumab-associated progressive multifocal leukoencephalopathy. [PDF]

Front Neurol
Glenn T, Berger JR, McEntire CRS.
europepmc   +1 more source

Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis. [PDF]

BMC Neurol
Alnajashi H, Almohammed HAJ, Morad AS, Bin Saddiq BW, Kushara KF, Al Zoabi BMK, Aldawsari WA, Almuhaysin FI, Gasim MA, Alharbi HA, Khan TN.   +10 more
europepmc   +1 more source

Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri). [PDF]

Brain Behav
Zibaoui RE, Ayoubi NKE, Khoury SJ.
europepmc   +1 more source

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. [PDF]

Brain
Giovannoni G, James L, Adeniran AA, Gold J, Young LS, Selwood DL, Baker D, Dobson R.   +7 more
europepmc   +1 more source